Nechansky, A, Kircheis R. (2010). Immunogenicity of therapeutics: a matter of efficacy and safety. Expert Opin. Drug Discov. 5(11):1-13.

Antes, B, Oberkleiner P, Nechansky, A, and Szolar, OHJ. (2010). Qualification of a microfluidics-based electrophoretic method for impurity testing of monoclonal antibodies. J. Pharm. Biomed. Anal. 51:743-9.

Nechansky, A (2010). HAHA - nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J. Pharm. Biomed. Anal. 51:252-4.

Nechansky, A, Szolar, OHJ, Siegl, P, Zinoecker, I, Halanek, I, Wiederkum, S, and Kircheis, R. (2009) Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the 'classical' radioactive method - qualification, comparison and application of the FACS based approach. J. Pharm. Biomed. Anal. 49: 1014-1020.

Nechansky, A, Grunt, S, Roitt, I, and Kircheis, R. (2008) Comparison of the Calibration Standards of Three Commercially Available Multiplex Kits for Human Cytokine Measurement to WHO Standards Reveals Striking Differences. Biomarkers Insight 3, 227-235.

Antes, B, Amon, S, Rizzi, A, Wiederkum, S, Kainer, M, Szolar, O, Fido, M, Kircheis, R, and Nechansky, A. (2007) Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. J. Chromatography B, 852: 250-256.

Szolar, OHJ, Stranner, S, Zinoecker, I, Himmler, G, Waxenecker, G, Mudde, GC, and Nechansky, A. (2006) Qualification and application of a surface plasmon resonance based assay monitoring HAHA responses induced after passive administration of a humanized anti-Lewis-Y antibody. J. Pharm. Biomed. Anal. 41:1347-1353.

For reprints please contact office@vela-labs.at